---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-034736"
form_type: "8-K"
ticker: "DCTH"
cik: "0000872912"
company_name: "DELCATH SYSTEMS, INC."
filed_at: "2024-08-05T23:59:59+00:00"
generated_at: "2026-05-31T13:18:42.968734+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Delcath Q2 revenue $7.8M vs $0.5M YoY; HEPZATO KIT generates $6.6M

## Summary
- Revenue $7.8M ($6.6M HEPZATO US, $1.2M CHEMOSAT Europe) vs $0.5M prior year.
- Cash and investments $19.9M; final principal payment submitted to Avenue Venture.
- Activated 8 US treating centers; received CMS NTAP status for HEPZATO (Aug 1, 2024).
- Appointed Dr. Bridget Martell to Board; extended melphalan supply agreement to 2028.
- FOCUS study results published in Annals of Surgical Oncology; accepted for ESMO poster.

## SEC filing metadata
- accession: 0001628280-24-034736
- form_type: 8-K
- ticker: DCTH
- cik: 0000872912
- company_name: DELCATH SYSTEMS, INC.
- filed_at: 2024-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872912/000162828024034736/0001628280-24-034736-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872912/000162828024034736/dcth-20240805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-034736
- JSON: https://secwatch.observer/filing/0001628280-24-034736.json
- Plain text: https://secwatch.observer/filing/0001628280-24-034736.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.